NantKwest: Continues To Sell Off Despite The Clinical Progress

 July 12, 2019 - 3:08 AM EDT
Print Email Article Font Down Font Up Charts



NantKwest: Continues To Sell Off Despite The Clinical Progress

My plan for my investment in NantKwest (NK) was to build a conservative position in anticipation that the market will start to identify the prospective upside in the stock. Indeed, NantKwest still has a couple of years from a potential product launch. Still, I expect CEO and founder Dr. Soon-Shiong will continue to validate NK-92's safety and efficacy in some the worst oncology indications, which should force the market to recognize the company's pivotal role in the Nant Cancer Vaccine. Regrettably, a few months have passed since I started a position in NK,

Read more ...


Source: SeekingAlpha (July 12, 2019 - 3:08 AM EDT)

News by QuoteMedia
www.quotemedia.com

Join the discussion